|
1
|
Perceptions of cancer patients and their physicians involved in phase I trials.
|
J Clin Oncol
|
1995
|
5.86
|
|
2
|
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
|
Br J Cancer
|
2006
|
4.93
|
|
3
|
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
|
Clin Pharmacol Ther
|
2012
|
3.15
|
|
4
|
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
|
Pharmacogenomics J
|
2002
|
2.77
|
|
5
|
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
|
J Clin Oncol
|
1998
|
2.69
|
|
6
|
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
|
J Clin Invest
|
1998
|
2.62
|
|
7
|
The pharmacogenetics research network: from SNP discovery to clinical drug response.
|
Clin Pharmacol Ther
|
2007
|
2.18
|
|
8
|
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
|
Clin Pharmacol Ther
|
1999
|
1.94
|
|
9
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
Clin Cancer Res
|
2000
|
1.93
|
|
10
|
Rapamycin: something old, something new, sometimes borrowed and now renewed.
|
Clin Pharmacol Ther
|
2007
|
1.90
|
|
11
|
Oral chemotherapy: rationale and future directions.
|
J Clin Oncol
|
1998
|
1.88
|
|
12
|
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
|
Cancer Res
|
1994
|
1.72
|
|
13
|
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
|
J Natl Cancer Inst
|
1999
|
1.70
|
|
14
|
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
|
IRB
|
2001
|
1.62
|
|
15
|
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
|
J Clin Oncol
|
2000
|
1.56
|
|
16
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
Clin Pharmacol Ther
|
2012
|
1.55
|
|
17
|
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
|
Cancer Invest
|
1999
|
1.47
|
|
18
|
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
|
J Natl Cancer Inst
|
1994
|
1.44
|
|
19
|
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
|
Blood
|
1990
|
1.44
|
|
20
|
Anticancer drug discovery and development throughout the world.
|
J Clin Oncol
|
2002
|
1.42
|
|
21
|
Body surface area as a determinant of pharmacokinetics and drug dosing.
|
Invest New Drugs
|
2001
|
1.35
|
|
22
|
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
|
J Clin Oncol
|
1992
|
1.24
|
|
23
|
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
|
Ann Oncol
|
1998
|
1.23
|
|
24
|
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
|
Drug Metab Dispos
|
2001
|
1.21
|
|
25
|
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
|
Cancer Chemother Pharmacol
|
1997
|
1.20
|
|
26
|
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
|
J Clin Oncol
|
1998
|
1.16
|
|
27
|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
|
Ann Oncol
|
2003
|
1.11
|
|
28
|
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
|
J Natl Cancer Inst
|
1997
|
1.07
|
|
29
|
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
|
J Clin Oncol
|
1997
|
1.03
|
|
30
|
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
|
Ann Oncol
|
2005
|
1.02
|
|
31
|
Biomarkers in early cancer drug development: limited utility.
|
Clin Pharmacol Ther
|
2009
|
1.01
|
|
32
|
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
|
J Natl Cancer Inst
|
1993
|
1.00
|
|
33
|
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin.
|
Clin Pharmacol Ther
|
1989
|
0.98
|
|
34
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
Clin Cancer Res
|
2000
|
0.98
|
|
35
|
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
|
Clin Exp Dermatol
|
2006
|
0.98
|
|
36
|
Prognostic factors for survival in patients treated in phase I clinical trials.
|
Cancer
|
1994
|
0.98
|
|
37
|
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
|
Pharmacogenomics J
|
2007
|
0.97
|
|
38
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
Clin Cancer Res
|
2001
|
0.97
|
|
39
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
Ann Oncol
|
2003
|
0.96
|
|
40
|
Pharmacogenetic pathway analysis of irinotecan.
|
Clin Pharmacol Ther
|
2008
|
0.95
|
|
41
|
Pharmacogenetics in cancer treatment.
|
Annu Rev Med
|
2001
|
0.95
|
|
42
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
J Clin Oncol
|
1998
|
0.95
|
|
43
|
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
|
Drug Metab Dispos
|
2001
|
0.95
|
|
44
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
Cancer
|
1989
|
0.94
|
|
45
|
Treatment of hairy cell leukemia with recombinant alpha 2 interferon.
|
Blood
|
1985
|
0.94
|
|
46
|
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
|
Clin Cancer Res
|
1995
|
0.94
|
|
47
|
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
|
J Clin Oncol
|
1996
|
0.94
|
|
48
|
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
|
Blood
|
1992
|
0.93
|
|
49
|
Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.
|
J Natl Cancer Inst
|
1992
|
0.93
|
|
50
|
Pharmacogenetics and cancer chemotherapy.
|
Eur J Cancer
|
1998
|
0.92
|
|
51
|
Cancer chemotherapy and skin changes.
|
Ann Intern Med
|
1985
|
0.92
|
|
52
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
Cancer Res
|
1994
|
0.92
|
|
53
|
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
|
Pharmacogenomics J
|
2008
|
0.91
|
|
54
|
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
|
J Natl Cancer Inst
|
1990
|
0.91
|
|
55
|
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
|
J Clin Oncol
|
1998
|
0.91
|
|
56
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
J Clin Oncol
|
1998
|
0.91
|
|
57
|
Pushing the envelope: informed consent in phase I trials.
|
Ann Oncol
|
1995
|
0.90
|
|
58
|
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
|
J Clin Oncol
|
1991
|
0.90
|
|
59
|
Skeletal complications in hairy cell leukemia: diagnosis and therapy.
|
J Clin Oncol
|
1988
|
0.90
|
|
60
|
Clinical pharmacology of camptothecins.
|
Cancer Chemother Pharmacol
|
1998
|
0.89
|
|
61
|
Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression.
|
Pharmacogenomics J
|
2012
|
0.89
|
|
62
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
J Clin Oncol
|
1993
|
0.89
|
|
63
|
Learning from our patients: one participant's impact on clinical trial research and informed consent.
|
Ann Intern Med
|
1997
|
0.88
|
|
64
|
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
|
Clin Pharmacol Ther
|
2009
|
0.87
|
|
65
|
Limited sampling model for area under the concentration time curve of total topotecan.
|
Clin Cancer Res
|
1996
|
0.87
|
|
66
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
Clin Cancer Res
|
1998
|
0.86
|
|
67
|
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
|
Eur J Cancer
|
1997
|
0.86
|
|
68
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
J Clin Oncol
|
1998
|
0.86
|
|
69
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
Ann Oncol
|
2004
|
0.85
|
|
70
|
Individualizing dosing of cancer chemotherapy.
|
Semin Oncol
|
1993
|
0.84
|
|
71
|
A population model for the leukopenic effect of etoposide.
|
Clin Pharmacol Ther
|
1995
|
0.83
|
|
72
|
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
|
Clin Cancer Res
|
1999
|
0.83
|
|
73
|
Interpatient and intrapatient variability in vinblastine pharmacokinetics.
|
Clin Pharmacol Ther
|
1987
|
0.82
|
|
74
|
A phase I study of intermittent infusion cladribine in patients with solid tumors.
|
Cancer
|
1994
|
0.82
|
|
75
|
Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer.
|
CPT Pharmacometrics Syst Pharmacol
|
2012
|
0.82
|
|
76
|
A limited sampling strategy for cyclophosphamide pharmacokinetics.
|
Cancer Res
|
1989
|
0.82
|
|
77
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
Cancer Chemother Pharmacol
|
1998
|
0.82
|
|
78
|
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
|
Clin Cancer Res
|
1995
|
0.82
|
|
79
|
Clinical trial designs for cytostatic agents.
|
J Clin Oncol
|
2001
|
0.82
|
|
80
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
J Clin Oncol
|
2001
|
0.81
|
|
81
|
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
|
Cancer Invest
|
2001
|
0.81
|
|
82
|
Nonprofit biomedical companies.
|
Clin Pharmacol Ther
|
2008
|
0.81
|
|
83
|
Evaluating the activity of temsirolimus in neuroendocrine cancer.
|
Br J Cancer
|
2006
|
0.81
|
|
84
|
Models of excellence: improving oncology drug development.
|
Clin Pharmacol Ther
|
2012
|
0.81
|
|
85
|
Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine.
|
Cancer Treat Rep
|
1986
|
0.81
|
|
86
|
Mineralocorticoid insufficiency due to suramin therapy.
|
Cancer
|
1996
|
0.81
|
|
87
|
Pharmacodynamics and long-term toxicity of etoposide.
|
Cancer Chemother Pharmacol
|
1994
|
0.81
|
|
88
|
Development of target-based antineoplastic agents.
|
Invest New Drugs
|
2000
|
0.81
|
|
89
|
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
|
Clin Cancer Res
|
1999
|
0.80
|
|
90
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
Ann Oncol
|
2001
|
0.80
|
|
91
|
Modeling interpatient pharmacodynamic variability of etoposide.
|
J Natl Cancer Inst
|
1991
|
0.80
|
|
92
|
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
|
Cancer Res
|
1996
|
0.79
|
|
93
|
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
|
J Natl Cancer Inst
|
1993
|
0.79
|
|
94
|
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
|
Am J Clin Oncol
|
2000
|
0.79
|
|
95
|
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
|
Clin Pharmacol Ther
|
1994
|
0.79
|
|
96
|
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
|
J Clin Oncol
|
1996
|
0.79
|
|
97
|
Are drug labels static or dynamic?
|
Clin Pharmacol Ther
|
2013
|
0.79
|
|
98
|
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
|
J Clin Oncol
|
1995
|
0.79
|
|
99
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
J Natl Cancer Inst
|
1994
|
0.79
|
|
100
|
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report.
|
Gynecol Oncol
|
1989
|
0.79
|
|
101
|
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
|
Cancer
|
1998
|
0.79
|
|
102
|
Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
|
Cancer Res
|
1989
|
0.79
|
|
103
|
Drug combinations: dangerous liaisons or great expectations?
|
Ann Oncol
|
1999
|
0.78
|
|
104
|
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
|
J Clin Oncol
|
1996
|
0.78
|
|
105
|
Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.
|
J Natl Cancer Inst
|
1988
|
0.78
|
|
106
|
Evaluation of Leu-M5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique.
|
Am J Clin Pathol
|
1988
|
0.78
|
|
107
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
Cancer Chemother Pharmacol
|
1991
|
0.77
|
|
108
|
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
|
J Clin Oncol
|
1988
|
0.77
|
|
109
|
The treatment of hairy cell leukemia: an update.
|
Leukemia
|
1992
|
0.77
|
|
110
|
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
|
Clin Cancer Res
|
1997
|
0.77
|
|
111
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
Eur J Cancer
|
2011
|
0.77
|
|
112
|
Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.
|
Semin Oncol
|
1988
|
0.77
|
|
113
|
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
|
Clin Cancer Res
|
2000
|
0.77
|
|
114
|
Update on pharmacogenetics in cancer chemotherapy.
|
Eur J Cancer
|
2002
|
0.77
|
|
115
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
J Clin Oncol
|
1996
|
0.77
|
|
116
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
Cancer
|
2001
|
0.77
|
|
117
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
J Clin Oncol
|
2001
|
0.76
|
|
118
|
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
|
Clin Pharmacokinet
|
2000
|
0.76
|
|
119
|
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
|
Semin Oncol
|
1987
|
0.76
|
|
120
|
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
|
Leuk Lymphoma
|
1994
|
0.76
|
|
121
|
Gazing into a crystal ball-cancer therapy in the post-genomic era.
|
Nat Med
|
2001
|
0.76
|
|
122
|
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
|
J Clin Oncol
|
1998
|
0.76
|
|
123
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
Cancer Chemother Pharmacol
|
1999
|
0.76
|
|
124
|
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
|
J Clin Oncol
|
1995
|
0.76
|
|
125
|
Pharmacodynamic modeling of prolonged administration of etoposide.
|
Cancer Chemother Pharmacol
|
1996
|
0.76
|
|
126
|
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.
|
Cancer Surv
|
1993
|
0.76
|
|
127
|
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
|
Semin Oncol
|
1992
|
0.75
|
|
128
|
Phase I and pharmacological study of vinblastine by prolonged continuous infusion.
|
Cancer Res
|
1986
|
0.75
|
|
129
|
New phase I trial methodology.
|
Semin Oncol
|
1997
|
0.75
|
|
130
|
Suramin: is adaptive control necessary?
|
J Clin Oncol
|
1992
|
0.75
|
|
131
|
Correspondence re: Xiu F. Hu et al., Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res., 50: 2953-2957, 1990.
|
Cancer Res
|
1991
|
0.75
|
|
132
|
Insights into the pharmacokinetics and pharmacodynamics of irinotecan.
|
Clin Cancer Res
|
2000
|
0.75
|
|
133
|
Duration of response after interferon treatment of hairy cell leukemia.
|
Blood
|
1990
|
0.75
|
|
134
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
Leuk Lymphoma
|
1994
|
0.75
|
|
135
|
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.
|
Br J Cancer
|
2002
|
0.75
|
|
136
|
Dose reduction of etoposide in jaundiced patients.
|
J Clin Oncol
|
1990
|
0.75
|
|
137
|
Conflict-of-interest policies.
|
N Engl J Med
|
2001
|
0.75
|
|
138
|
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
|
Blood
|
1987
|
0.75
|
|
139
|
Phase I study of escalating does of carboplatin.
|
Cancer Chemother Pharmacol
|
1994
|
0.75
|
|
140
|
Modulation of vinblastine resistance with cyclosporine: a phase I study.
|
Clin Pharmacol Ther
|
1993
|
0.75
|
|
141
|
Playing Russian roulette with tyrosine kinase inhibitors.
|
Clin Pharmacol Ther
|
2012
|
0.75
|
|
142
|
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
|
Cancer Chemother Pharmacol
|
2000
|
0.75
|
|
143
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
J Clin Oncol
|
1998
|
0.75
|
|
144
|
Recent advances in the treatment of hairy-cell leukemia.
|
N Engl J Med
|
1987
|
0.75
|
|
145
|
Evaluation of neuropathy in patients on suramin treatment.
|
Muscle Nerve
|
1997
|
0.75
|
|
146
|
Sequential treatment of hairy cell leukemia: a new role for interferon.
|
Important Adv Oncol
|
1986
|
0.75
|
|
147
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
Cancer Chemother Pharmacol
|
1992
|
0.75
|
|
148
|
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
|
J Clin Oncol
|
1996
|
0.75
|
|
149
|
Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma.
|
Am J Hematol
|
1988
|
0.75
|
|
150
|
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
|
Eur J Cancer
|
1991
|
0.75
|
|
151
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
Ann Oncol
|
1993
|
0.75
|
|
152
|
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
|
J Clin Oncol
|
1987
|
0.75
|
|
153
|
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
|
Oncology (Williston Park)
|
1997
|
0.75
|
|
154
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
Clin Pharmacol Ther
|
1996
|
0.75
|
|
155
|
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
|
Cancer Res
|
1993
|
0.75
|
|
156
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
Cancer Chemother Pharmacol
|
1993
|
0.75
|
|
157
|
Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.
|
Leukemia
|
1987
|
0.75
|
|
158
|
Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia.
|
Am J Clin Pathol
|
1986
|
0.75
|
|
159
|
Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.
|
Leukemia
|
1992
|
0.75
|
|
160
|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
|
Cancer Chemother Pharmacol
|
1995
|
0.75
|
|
161
|
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
|
J Natl Cancer Inst
|
1989
|
0.75
|
|
162
|
Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor.
|
Ann Oncol
|
1991
|
0.75
|
|
163
|
The role of interferon in the treatment of hairy cell leukemia.
|
Semin Oncol
|
1986
|
0.75
|
|
164
|
What is the choice of treatment for hairy cell leukemia?
|
J Clin Oncol
|
1989
|
0.75
|
|
165
|
Elimination pathways of [14C]losoxantrone in four cancer patients.
|
Drug Metab Dispos
|
2001
|
0.75
|
|
166
|
Pharmacogenetics in cancer etiology and chemotherapy.
|
Clin Cancer Res
|
1997
|
0.75
|
|
167
|
Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy.
|
Cancer
|
1987
|
0.75
|
|
168
|
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
|
Cancer Chemother Pharmacol
|
1993
|
0.75
|
|
169
|
Hairy cell leukemia. Current management.
|
Hematol Oncol Clin North Am
|
1990
|
0.75
|
|
170
|
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
|
Cancer
|
1996
|
0.75
|
|
171
|
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
|
Cancer Res
|
1986
|
0.75
|
|
172
|
Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine.
|
J Clin Oncol
|
1992
|
0.75
|
|
173
|
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.
|
Cancer Chemother Pharmacol
|
1993
|
0.75
|
|
174
|
Promising new agents in oncologic treatment.
|
Curr Opin Oncol
|
1996
|
0.75
|
|
175
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
Cancer Chemother Pharmacol
|
1994
|
0.75
|
|
176
|
Data modifications to phase I study of suramin.
|
J Clin Oncol
|
1996
|
0.75
|
|
177
|
Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.
|
Cancer Chemother Pharmacol
|
1997
|
0.75
|
|
178
|
Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns.
|
J Chromatogr B Biomed Sci Appl
|
1998
|
0.75
|
|
179
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
Cancer Res
|
1986
|
0.75
|
|
180
|
Hairy cell leukaemia: the role of alpha interferon.
|
Eur J Cancer
|
1991
|
0.75
|
|
181
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
Cancer Chemother Pharmacol
|
1997
|
0.75
|
|
182
|
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
|
Cancer
|
1999
|
0.75
|
|
183
|
New perspectives on the toxicity of etoposide.
|
Semin Oncol
|
1992
|
0.75
|